CryoPort

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CryoPort achieves record revenue, eyes growth in cell therapy logistics

CryoPort's Q4 2022 performance reflects robust revenue growth and strategic investments, positioning the company for further expansion in cell and gene therapy logistics.
While facing challenges in manufacturing capacity and supply chain, CryoPort's focus on revenue diversification and margin improvement initiatives strengthens its competitive position.
The company's outlook for 2023 is optimistic, with opportunities in supporting commercial therapies, market share expansion, and new product launches driving growth.

CryoPort (CYRX) reports strong Q1 revenue growth and eyes global expansion

CryoPort's Q1 performance reflects robust revenue growth and strategic advancements in logistics solutions.
While facing industry challenges and capacity constraints, CryoPort is leveraging opportunities for expansion and innovation.
The company's focus on acquisitions, partnerships, and market growth positions it well for future success.
Investments in capabilities and global expansion underscore CryoPort's commitment to driving revenue and operational excellence.

CryoPort reports Q2 revenue impact from China, remains confident in growth

CryoPort faces challenges from China's economic conditions but remains confident in its long-term growth drivers in the cell and gene therapy industry.
Strategic investments in technology, premium product positioning, and operational enhancements are key strengths driving future growth and competitiveness.
Navigating short-term challenges, seizing expansion opportunities, and leveraging synergies with MVE in China are crucial for CryoPort's future success.

CryoPort reports robust Q3 earnings, eyes growth in life sciences

CryoPort's Q3 results met expectations, showcasing growth in revenue and execution of its corporate strategy for long-term profitability.
The company's performance reflects strong demand, strategic acquisitions, and a focus on innovation and customer service.
While facing challenges like manufacturing capacity and rising costs, CryoPort remains well-positioned to capitalize on market opportunities.
With a clear outlook for future growth and a stable financial position, CryoPort is poised for continued success in the life sciences industry.

CryoPort reports strong revenue, eyes cell therapy growth in 2024

CryoPort's FY 2023 performance driven by service revenue and global clinical trial support.
Focused on revenue growth in cell and gene therapy industry, introducing innovative products.
Addressing challenges in market competition, revenue trends, and debt management.
Positioned for progressive advancement in 2024, capitalizing on market opportunities.

Cryoport maintains revenue guidance amidst challenges, eyes growth opportunities

Cryoport maintains revenue guidance despite Q1 challenges, focusing on growth drivers and cost-saving measures for improved financial performance.
Strong cash balance, collaborations with logistics companies, and ongoing revenue growth initiatives position Cryoport for future success.
Challenges in MVE business and biologistics revenue softness require attention, but opportunities lie in financial improvement and revenue growth drivers.
Anticipation of continuous progression in the second half and positive integration with CRYOPDP highlight growth prospects for Cryoport.

CryoPort reports strong Q2 revenue growth, eyes profitability by 2025

CryoPort's Q2 2024 performance reflects robust revenue growth and cost-saving initiatives.
While facing challenges in soft demand and market conditions, the company eyes growth opportunities.
Confidence in revenue guidance and proactive measures signal a strategic path to profitability.
Strengthening commercial revenue and upcoming facility openings position CryoPort for future growth.

CryoPort reports Q3 growth, focuses on profitability and cost reduction

CryoPort's Q3 performance showcased growth in Life Sciences Services and strategic initiatives to drive profitability.
Despite challenges in the life sciences sector and uneven market recovery in MVE division, CryoPort remains focused on cost reduction and long-term growth.
Opportunities lie in new product launches, high-value contract acquisitions, and maintaining financial strength post-election.
Overall, CryoPort's resilience and strategic focus position the company for sustained growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Partnership Establishes Cryoport Systems' First U.K. Logistics Center to Support Future Expansion and Provide End-to-End Supply Chain Solutions for Advanced Therapy Manufacturers NASHVILLE, Tenn. and STEVENAGE, United Kingdom , Oct. 10, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and the Cell and Gene Therapy Catapult ("CGT Catapult"), an independent innovation and technology organisation specializing in the advancement of cell and gene therapies, today announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies.

Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies

Partnership will provide access to standardized and optimized apheresis collection, cryopreservation and bioprocessing processes throughout the U.S. and Europe MINNEAPOLIS and NASHVILLE, Tenn. , Oct. 9, 2023 /PRNewswire/ -- Be The Match BioTherapies® , an organization offering solutions for companies developing and commercializing cell and gene therapies, and Cryoport (NASDAQ: CYRX), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced a new strategic partnership.

Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies

Company Named "Best Cell & Gene Therapy Supplier – Cryogenic Storage" NASHVILLE, Tenn. , Sept. 14, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company has been named "Best Cell & Gene Therapy Supplier – Cryogenic Storage" as part of this year's IMAPAC Asia Pacific Cell & Gene Therapy Excellence Awards.

Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to.

The Law Offices of Frank R. Cruz Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cryoport investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your conta.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) investors concerning the Company's possible violations of federal securities laws. On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to be in the range of $56.5 to $57.5 million, representing a decrease of 11%, a.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm

Cryoport, Inc. (NASDAQ:CYRX ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Corporate Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Puneet Souda - SVB Securities David Saxon - Needham & Company Lucas Beaumont - UBS David Larsen - BTIG Yuan Zhi - B. Riley Richard Baldry - ROTH MKM Brandon Couillard - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Cryoport Second Quarter 2023 Earnings Conference Call.

Cryoport, Inc. (CYRX) Q2 2023 Earnings Call Transcript

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.17 per share a year ago.

CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates

Second quarter revenue of $57 million, in line with previously announced preliminary results Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of 42 new trials added year-over-year Strong balance sheet with over $500 million in cash and short-term investments NASHVILLE, Tenn. , Aug. 9, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced financial results for the second quarter (Q2) and first half (H1) of 2023.

Cryoport Reports Second Quarter 2023 Financial Results

NEW YORK , Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or the "Company") (NASDAQ: CYRX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cryoport, Inc. - CYRX

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with LossesIn Excess of $100,000 to Contact the Firm

NASHVILLE, Tenn. , Aug. 2, 2023 /PRNewswire/ --  Cry oport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, reproductive medicine and animal health industries, today announced that the Company will report financial results for the second quarter ended June 30, 2023 on Wednesday, August 9, 2023 after U.S. markets close.

Cryoport to Report Second Quarter 2023 Financial Results on August 9, 2023

LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE: CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $CYRX #CYRX--The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NYSE:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cryoport investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) investors concerning the Company's possible violations of federal securities laws. On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to be in the range of $56.5 to $57.5 million, representing a decrease of 11%, at.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

Cryoport released preliminary Q2 results, projecting sales to fall behind The Street's estimates. Lower demand for Cryoport's capital equipment and delays in initiating clinical trials are key reasons behind the changes. Management remains optimistic, but the investment facts do not corroborate a buy rating at this point in time in my view.

Cryoport: Revising To Hold After Major Changes To Forecasts, Sentiment

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to b.

The Law Offices of Frank R. Cruz Announces Investigation of Cryoport, Inc. (CYRX) on Behalf of Investors

Cryoport downgraded annual guidance. The company has seen a slowdown in orders from gene therapy and cell therapy clients.

Why Shares of Cryoport are Tumbling Thursday

CryoPort (NASDAQ: CYRX ) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for the second quarter of 2023. The bad news for investors in CYRX stock starts with its expected revenue of $56.5 million to $57.5 million for the quarter.

News for CryoPort Stock (CYRX)